Explore ›
Finding
Finding
null
Disease burden at start of bridging chemotherapy (high vs low), disease burden prior to lymphodepleting chemotherapy (high vs low), and tumor debulking by bridging chemotherapy did not significantly affect clinical outcomes after CAR T cell therapy in this cohort.
| Comparator | Low disease burden at start of bridging chemotherapy or prior to LDC |
| Effect summary | null |
Connected entities
Interventions
Populations
Source
PMC9361393
Impact of Bridging Chemotherapy on Clinical Outcomes of CD19-Specific CAR T Cell Therapy in Children/Young Adults with Relapsed/Refractory B Cell Acute Lymphoblastic Leukemia